Guided Therapeutics (GTHP) Receivables - Net (2016 - 2025)
Guided Therapeutics' Receivables - Net history spans 16 years, with the latest figure at $2000.0 for Q3 2025.
- For Q3 2025, Receivables - Net changed N/A year-over-year to $2000.0; the TTM value through Sep 2025 reached $2000.0, changed N/A, while the annual FY2024 figure was $3000.0, 59.69% down from the prior year.
- Receivables - Net for Q3 2025 was $2000.0 at Guided Therapeutics, down from $8000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $126000.0 in Q2 2021 and bottomed at $2000.0 in Q2 2024.
- The 5-year median for Receivables - Net is $8471.0 (2023), against an average of $43563.1.
- The largest YoY upside for Receivables - Net was 425.0% in 2022 against a maximum downside of 94.99% in 2022.
- A 5-year view of Receivables - Net shows it stood at $126000.0 in 2021, then plummeted by 94.99% to $6312.0 in 2022, then grew by 10.9% to $7000.0 in 2023, then plummeted by 57.14% to $3000.0 in 2024, then tumbled by 33.33% to $2000.0 in 2025.
- Per Business Quant, the three most recent readings for GTHP's Receivables - Net are $2000.0 (Q3 2025), $8000.0 (Q2 2025), and $2000.0 (Q1 2025).